Molecular findings and antibiotic-resistance in an outbreak of Acinetobacter baumannii in an intensive care unit

Annali dell'Istituto Superiore di Sanita

Volumn 43, Issue 1, 2007, Pages 83-88

  Longo, Benedetta ^a   Pantosti, Annalisa ^a   Luzzi, Ida ^a   Tarasi, Agapito ^b   Di Sora, Fiorella ^b   Gallo, Stella ^b   Placanica, Paola ^c   Monaco, Monica ^a   Dionisi, Anna Maria ^a   Volpe, Italo ^d   Montella, Francesco ^b   Cassone, Antonio ^a   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Immunologia Clinica   (Italy)

^c Dipartimento di Microbiologia   (Italy)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Acinetobacter baumannii; Intensive care unit; Multi drug resistance; Outbreak

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; COLISTIN; RIFAMPICIN; SULBACTAM; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CROSS INFECTION; DISINFECTION; DRUG EFFECT; EPIDEMIC; FEMALE; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; ITALY; LUNG LAVAGE; MALE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PATIENT CARE; PULSED FIELD GEL ELECTROPHORESIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CARBAPENEMS; COLISTIN; CROSS INFECTION; DISEASE OUTBREAKS; DISINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT ISOLATION; RIFAMPIN; ROME; SULBACTAM;

EID: 34250620986     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control and Hasp Epiedemiol 2003;24:284-95.
2. Wendt C, Dietze B, Dietze E, Ruden H. Survival of Acinetobacter baumanni on dry surfaces. J Clin Microbiol 1997;35:1394-7.
3. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as a nosocomial pathogen: microbiologic, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
4. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, Gordon SM. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115:1378-82.
5. Longo B, Pantosti A, Luzzi I, Placanica P, Gallo S, Tarasi A, Di Sora F, Monaco M, Dionisi AM, Volpe I, Montella F, Cassone A, Rezza G. An outbreak of Acinetobacter baumannii in an intensive care unit: epidemiological and molecular findings. J Hasp Infect 2006;64:303-5.
6. Clinical Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Fifteen informational supplement; M100-S15. Wayne, PA: CLSI; 2005.
7. Gales AC, Reis OA, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polimixin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90.
8. Peters TM, Maguire C, Threlfall EJ, Fisher IS, Gill N, Gatto AJ, Salm-gene project. The Salm-gene project - a European collaboration for DNA fingerprinting for food-related salmonellosis. Euro Surveill 2003;8:46-50.
9. Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, Villari P. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004;42:946-53.
10. Higgins PG, Wisplinghoff H, Stefanik D, Seifen H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains, Antimicrob Agents Chemother 2004;48:1586-92.
11. Rhomberg PR, Jones RN, MYSTIC Program (USA) Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003;47:365-72.
12. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004;3:14-4.
13. Van Looveren M, Goossens H, ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704.
14. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. Collected over 10 years in three continents. Antimicrob Agents Chemother 2006;50:756-8.
15. Bertini A, Giordano A, Varesi P, Villa L, Mancini C, Carattoli A. First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy, [letter] Antimicrob Agents Chemother 2006;50:2268-9.
16. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8.
17. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E.Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-3.